Key Highlights

  • Net loss per share was USD 0.32 against an estimate of USD 0.34; net loss was USD 20.29 million.
  • Cash, cash equivalents and Investment securities were USD 208.6 million at September 30, against USD 219.8 million in December.
  • Research and development expense was USD 16.93 million against USD 14.59 million, including DM1 program costs of USD 3.35 million.
  • The company reported no Revenue and is modifying RESTORE-FA cohorts, with a registrational plan update scheduled for the fourth quarter.

Design Therapeutics, Inc. (NASDAQ:DSGN) reported that, after four-week data from RESTORE-FA, a Phase 1/2 study of DT-216P2 in Friedreich ataxia, it is modifying the ongoing cohorts, keeping 1 mpk as the go-forward dose, enrolling 10 patients in a 12-week cohort and naming blood FXN protein change from baseline as the primary efficacy endpoint. As a clinical-stage company it has no revenue, and its net loss per share was USD 0.32 against an estimate of USD 0.34.

How the Trial Update Fits the Quarter

The company described the May 2026 four-week intravenous data as positive. At the 1 mpk dose (four patients), mean improvements from baseline were 6.4 points on the mFARS scale and 2.7 points on the upright stability score. Whole blood FXN mRNA rose 65% from baseline, and muscle FXN mRNA rose 42%. No serious adverse events or treatment discontinuations were reported, and transient ALT elevations in three patients were asymptomatic.

Other programs moved in parallel. A Phase 1 multiple ascending dose trial of DT-818 in myotonic dystrophy type 1 began dosing in the first half of 2026, and the Huntington's disease work remains preclinical. For DT-168 in Fuchs endothelial corneal dystrophy, the company enrolled about 250 patients in an observational study and selected about 100 for follow-up.

Results Around the Event

Research and development expense was USD 16.93 million against USD 14.59 million. By program, FA cost USD 4.75 million against USD 3.45 million, DM1 cost USD 3.35 million (now reported separately after moving into clinical development), and FECD cost USD 0.51 million against USD 1.58 million. General and administrative expense was USD 5.30 million against USD 4.72 million, and total operating expenses were USD 22.23 million against USD 19.31 million.

Net loss was USD 20.29 million against USD 17.00 million a year earlier. Interest income was USD 1.94 million against USD 2.31 million. For the nine months, net loss was USD 58.09 million against USD 53.80 million.

Financing, Cash and the Funding Statement

Cash, cash equivalents and investment securities totaled USD 208.6 million, against USD 219.8 million at December 31, 2025. Nine-month operating cash use was USD 47.3 million against USD 42.4 million, and financing provided USD 38.1 million, mostly from selling 3,140,522 shares through the at-the-market program for net proceeds of about USD 37.1 million.

USD 36.4 million remained available under that program at September 30. The company stated it intends to file a prospectus supplement raising the program to USD 200.0 million, within a USD 300.0 million shelf registration. Management said existing resources cover planned operating and Capital needs for more than the next 12 months, and that accumulated Deficit was USD 355.1 million.

Guidance Versus Reported Results

A net loss of USD 20.29 million sits alongside USD 208.6 million of cash and securities, USD 16.93 million of Research and Development spending and a USD 355.1 million accumulated deficit. The company gave no financial guidance.

It did name dated items: an update on registrational plans in the fourth quarter of 2026, RESTORE-FA 12-week data in the first quarter of 2027, and DT-818 Phase 1 and DT-168 Phase 2 biomarker data in 2027. It also stated that it plans to raise its at-the-market capacity to USD 200.0 million.